{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T02:10:42Z","timestamp":1743559842980,"version":"3.40.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"DOI":"10.7759\/cureus.81586","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T01:36:18Z","timestamp":1743557778000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of BRAF-V600E-Positive Pulmonary Pleomorphic Carcinoma Successfully Treated With Dabrafenib and Trametinib Administered via a Percutaneous Endoscopic Gastrojejunostomy Tube for Ileus Caused by Small Intestinal Metastasis"],"prefix":"10.7759","author":[{"given":"Jukiya","family":"Higashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotoko","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Nakaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Miyagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.04.018","article-title":"Pleomorphic carcinoma of the lung: a surgical outcome","volume":"134","author":"Yuki T","year":"2007","unstructured":"Yuki T, Sakuma T, Ohbayashi C, Yoshimura M, Tsubota N, Okita Y, Okada M. Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg. 2007, 134:399-404. 10.1016\/j.jtcvs.2007.04.018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-5002(01)00224-0","article-title":"Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma","volume":"34","author":"Chang YL","year":"2001","unstructured":"Chang YL, Lee YC, Shih JY, Wu CT. Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer. 2001, 34:91-7. 10.1016\/s0169-5002(01)00224-0","journal-title":"Lung Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.06.002","article-title":"Clinical characteristics of pleomorphic carcinoma of the lung","volume":"68","author":"Ito K","year":"2010","unstructured":"Ito K, Oizumi S, Fukumoto S, et al.. Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer. 2010, 68:204-10. 10.1016\/j.lungcan.2009.06.002","journal-title":"Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-2826","article-title":"Clinicopathological features and prognostic analysis of metastatic pulmonary sarcomatoid carcinoma: a SEER analysis","volume":"13","author":"Xiao C","year":"2021","unstructured":"Xiao C, Yang X, Hao J, Guo C, Pu Q, Liu L. Clinicopathological features and prognostic analysis of metastatic pulmonary sarcomatoid carcinoma: a SEER analysis. J Thorac Dis. 2021, 13:893-905. 10.21037\/jtd-20-2826","journal-title":"J Thorac Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.05.006","article-title":"Palliative chemotherapy for pulmonary pleomorphic carcinoma","volume":"58","author":"Bae HM","year":"2007","unstructured":"Bae HM, Min HS, Lee SH, et al.. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer. 2007, 58:112-5. 10.1016\/j.lungcan.2007.05.006","journal-title":"Lung Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12505","article-title":"Case series of pleomorphic carcinomas of the lung treated with nivolumab","volume":"8","author":"Kanazu M","year":"2017","unstructured":"Kanazu M, Uenami T, Yano Y, et al.. Case series of pleomorphic carcinomas of the lung treated with nivolumab. Thorac Cancer. 2017, 8:724-8. 10.1111\/1759-7714.12505","journal-title":"Thorac Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.12.013","article-title":"To crush or not to crush: administering dabrafenib and trametinib through a nasogastric tube in a critically ill patient with nonsmall cell lung cancer - a case report and review of literature of targeted therapies given through enteral feeding tubes","volume":"25","author":"Jang C","year":"2024","unstructured":"Jang C, Lau SC, Velcheti V. To crush or not to crush: administering dabrafenib and trametinib through a nasogastric tube in a critically ill patient with nonsmall cell lung cancer - a case report and review of literature of targeted therapies given through enteral feeding tubes. Clin Lung Cancer. 2024, 25:e124-8. 10.1016\/j.cllc.2023.12.013","journal-title":"Clin Lung Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard D","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJ, et al.. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017, 18:1307-16. 10.1016\/S1470-2045(17)30679-4","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00201-3","article-title":"Comprehensive molecular profiling of pulmonary pleomorphic carcinoma","volume":"5","author":"Nagano M","year":"2021","unstructured":"Nagano M, Kohsaka S, Hayashi T, et al.. Comprehensive molecular profiling of pulmonary pleomorphic carcinoma. NPJ Precis Oncol. 2021, 5:57. 10.1038\/s41698-021-00201-3","journal-title":"NPJ Precis Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231175087","article-title":"Extemporaneous compounding of dabrafenib and trametinib for cancer patients with feeding tubes","volume":"29","author":"Bui T","year":"2023","unstructured":"Bui T, Vu V, Luon D. Extemporaneous compounding of dabrafenib and trametinib for cancer patients with feeding tubes. J Oncol Pharm Pract. 2023, 29:1498-502. 10.1177\/10781552231175087","journal-title":"J Oncol Pharm Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.973","article-title":"Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status","volume":"5","author":"Kanai O","year":"2017","unstructured":"Kanai O, Kim YH, Nakatani K, Fujita K, Mio T. Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status. Clin Case Rep. 2017, 5:927-30. 10.1002\/ccr3.973","journal-title":"Clin Case Rep"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.2482\/haigan.62.341","article-title":"A case of ALK-positive lung cancer that responded to brigatinib administered via gastrostomy using a simple suspension method","volume":"62","author":"Goto H","year":"2022","unstructured":"Goto H, Yoshida M, Miki H, et al.. A case of ALK-positive lung cancer that responded to brigatinib administered via gastrostomy using a simple suspension method. Jpn J Lung Cancer. 2022, 62:341-4.","journal-title":"Jpn J Lung Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2012.12.001","article-title":"Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status","volume":"51","author":"Tamai K","year":"2013","unstructured":"Tamai K, Nagata K, Otsuka K, et al.. Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status. Respir Investig. 2013, 51:46-8. 10.1016\/j.resinv.2012.12.001","journal-title":"Respir Investig"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.4993\/acrt.27.24","article-title":"Administration of crizotinib through gastrostoma resolves esophageal occlusion caused by lymph node metastasis of squamous cell lung cancer with ROS1 fusion gene: a case report","volume":"27","author":"Nakayama M","year":"2019","unstructured":"Nakayama M, Nagai Y, Uchiyama A, et al.. Administration of crizotinib through gastrostoma resolves esophageal occlusion caused by lymph node metastasis of squamous cell lung cancer with ROS1 fusion gene: a case report. Ann Cancer Res Ther. 2019, 27:24-7.","journal-title":"Ann Cancer Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1256930","article-title":"Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing","volume":"346","author":"Zhang J","year":"2014","unstructured":"Zhang J, Fujimoto J, Zhang J, et al.. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014, 346:256-9. 10.1126\/science.1256930","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani M","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, et al.. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017, 376:2109-21. 10.1056\/NEJMoa1616288","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyn155","article-title":"Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome","volume":"39","author":"Ushiki A","year":"2009","unstructured":"Ushiki A, Koizumi T, Kobayashi N, et al.. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol. 2009, 39:267-70. 10.1093\/jjco\/hyn155","journal-title":"Jpn J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/339531-a-case-of-braf-v600e-positive-pulmonary-pleomorphic-carcinoma-successfully-treated-with-dabrafenib-and-trametinib-administered-via-a-percutaneous-endoscopic-gastrojejunostomy-tube-for-ileus-caused-by-small-intestinal-metastasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T01:36:20Z","timestamp":1743557780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/339531-a-case-of-braf-v600e-positive-pulmonary-pleomorphic-carcinoma-successfully-treated-with-dabrafenib-and-trametinib-administered-via-a-percutaneous-endoscopic-gastrojejunostomy-tube-for-ileus-caused-by-small-intestinal-metastasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.81586","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}